Consensus C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6.24 ^USD	-3.55%		-9.70%	+10.44%

Apr. 08	C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	CI
Mar. 18	C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index	CI

Evolution of the average Target Price on C4 Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b1fa14b8ae19644bc4b6cb4.1gWIWrrXdrbcCMWA4yigOvwwPNVrWu3eP5jPMnMDgZc.4Hy6Gc-IJum-Zo7jpRiWaowDRuE9LrjubfyQCzd36c3jcbsR27o0jqlKlA~497348055cf4073fa026828499d1e196

Analyst Recommendations on C4 Therapeutics, Inc.

Morgan Stanley Adjusts Price Target on C4 Therapeutics to $8 From $1, Maintains Equal-Weight Rating	Feb. 26	MT
JPMorgan Upgrades C4 Therapeutics to Neutral From Underweight, Price Target is $6	Jan. 29	MT
Stifel Upgrades C4 Therapeutics to Buy From Hold, Raises Price Target to $12 From $2	Dec. 13	MT
Morgan Stanley Upgrades C4 Therapeutics to Equalweight From Underweight, Cuts Price Target to $1 From $3	Nov. 06	MT
BMO Capital Adjusts Price Target on C4 Therapeutics to $16 From $18, Keeps Outperform Rating	Nov. 03	MT
HC Wainwright Adjusts Price Target on C4 Therapeutics to $7 From $17, Keeps Buy Rating	Nov. 02	MT
HC Wainwright Adjusts Price Target on C4 Therapeutics to $17 From $25, Maintains Buy Rating	23-08-09	MT
UBS Adjusts C4 Therapeutics Price Target to $20 From $22, Maintains Buy Rating	23-07-21	MT
Evercore ISI Adjusts C4 Therapeutics Price Target to $10 From $20, Maintains Outperform Rating	23-05-30	MT
Morgan Stanley Adjusts Price Target on C4 Therapeutics to $3 From $5, Maintains Underweight Rating	23-05-12	MT
HC Wainwright Adjusts C4 Therapeutics' Price Target to $25 From $35, Keeps Buy Rating	23-05-08	MT
BofA Securities Lowers Price Target on C4 Therapeutics to $5 From $11, Maintains Neutral Rating	23-03-28	MT
Morgan Stanley Adjusts Price Target on C4 Therapeutics to $5 From $6, Maintains Underweight Rating	23-02-27	MT
UBS Adjusts C4 Therapeutics Price Target to $22 From $24, Maintains Buy Rating	23-02-24	MT
JPMorgan Chase Downgrades C4 Therapeutics to Underweight From Neutral, Lowers Price Target to $5 From $15	23-02-24	MT
Wells Fargo Adjusts Price Target on C4 Therapeutics to $11 From $12, Maintains Equal-Weight Rating	22-11-08	MT
UBS Adjusts C4 Therapeutics Price Target to $24 From $26, Maintains Buy Rating	22-11-04	MT
JPMorgan Downgrades C4 Therapeutics to Neutral From Overweight, Adjusts Price Target to $15 From $22	22-11-04	MT
Morgan Stanley Starts C4 Therapeutics at Underweight With $6 Price Target	22-10-11	MT
Credit Suisse Raises C4 Therapeutics' Price Target to $12 from $10, Keeps Underperform Rating	22-08-05	MT
HC Wainwright Adjusts Price Target on C4 Therapeutics to $35 From $63, Reiterates Buy Rating	22-05-09	MT
Credit Suisse Initiates C4 Therapeutics at Underperform with $10 Price Target, Says Risk Related to Lead Program Too High	22-04-28	MT
UBS Adjusts C4 Therapeutics Price Target to $26 From $64, Maintains Buy Rating	22-04-18	MT
SVB Leerink Adjusts C4 Therapeutics Price Target to $25 From $40, Maintains Outperform Rating	22-04-11	MT
Stifel Adjusts C4 Therapeutics' Price Target to $15 From $28, Reiterates Hold Rating	22-04-11	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.24 USD

Average target price

17.22 USD

Spread / Average Target

+176.00%

High Price Target

60 USD

Spread / Highest target

+861.54%

Low Price Target

7 USD

Spread / Lowest Target

+12.18%

Consensus detail

Consensus revision (last 18 months)

Analysts covering C4 Therapeutics, Inc.

Morgan Stanley
JPMorgan Chase
Stifel Nicolaus
BMO Capital
HC Wainwright
UBS
Evercore ISI
BofA Securities
Wells Fargo Securities
Credit Suisse
SVB Leerink
Brookline Capital Management

Ratings for C4 Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar